Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunder Biomedical Tech CoROCO:4115 +0.38%52 EBITDA Margin % is 13.34% as of Dec. 2025, which is 7% above its 10-year median of 12.42. GuruFocus rates ROCO:4115 with a GF Score™ of 52/100 and a GF Value™ of NT$10.70 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Sunder Biomedical Tech Co ranks better than 53.98% on this metric.
Sunder Biomedical Tech Co (ROCO:4115) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sunder Biomedical Tech Co EBITDA Margin % Related Terms
Sunder Biomedical Tech Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4115 vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Sunder Biomedical Tech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunder Biomedical Tech Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sunder Biomedical Tech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sunder Biomedical Tech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunder Biomedical Tech Co (ROCO:4115) has a EBITDA Margin % of 13.34% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sunder Biomedical Tech Co and its competitors. This is near median its historical median of 12.42. Over the past decade, Sunder Biomedical Tech Co's EBITDA Margin % has ranged from 8.92 to 17.00. According to the industry distribution chart, Sunder Biomedical Tech Co ranks #376 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 46%.
Is Sunder Biomedical Tech Co's EBITDA Margin % too high?
Sunder Biomedical Tech Co's current EBITDA Margin % of 13.34% is near median its 10-year median of 12.42. Over the past 10 years, this metric has ranged from a low of 8.92 to a high of 17.00. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. Sunder Biomedical Tech Co's value of 13.34% is 79.3% above this industry median. Based on the distribution chart, Sunder Biomedical Tech Co ranks #376 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sunder Biomedical Tech Co has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunder Biomedical Tech Co's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sunder Biomedical Tech Co ranks #376 out of 817 companies for EBITDA Margin %. This puts Sunder Biomedical Tech Co in the upper half of its industry. The industry median EBITDA Margin % is 7.44. Sunder Biomedical Tech Co's value of 13.34% is 79.3% above this benchmark. Historically, Sunder Biomedical Tech Co's own EBITDA Margin % has ranged from 8.92 to 17.00 over the past decade. While the company's 10-year median is 12.42 vs. the industry median of 7.44, Sunder Biomedical Tech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunder Biomedical Tech Co's current EBITDA Margin % of 13.34% is 79.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sunder Biomedical Tech Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunder Biomedical Tech Co's current EBITDA Margin % is 13.34%, which is near median its own 10-year median of 12.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunder Biomedical Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Sunder Biomedical Tech Co (ROCO:4115) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$10.70, compared to a current price of NT$7.86 — trading 26.5% below its estimated fair value. The current EBITDA Margin % is 13.34%, which is near median its 10-year median of 12.42 and 79.3% above the Medical Devices & Instruments industry median of 7.44. Sunder Biomedical Tech Co's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sunder Biomedical Tech Co (ROCO:4115), the current EBITDA Margin % is 13.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunder Biomedical Tech Co (ROCO:4115) Overvalued in 2026?
Based on GuruFocus' analysis, Sunder Biomedical Tech Co stock appears to be undervalued.
The current stock price of NT$7.86 is trading 26.5% below its estimated GF Value™ of NT$10.70.
GuruFocus considers Sunder Biomedical Tech Co to be Modestly Undervalued.
Key valuation signals for ROCO:4115:
EBITDA Margin %: 13.34% (near median its 10-year median of 12.42)
GF Value™: NT$10.70 vs. price of NT$7.86 (26.5% below fair value)
Industry Position: 79.3% above the Medical Devices & Instruments median (#376 of 817)
No single metric tells the full story. See the ROCO:4115 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunder Biomedical Tech Co Ltd is engaged in providing medical devices. Its products include Protective Goggles; Meltblown Nonwoven Fabric/Mask; Suction Irrigation Set; Smoke Filter; Endo Bag; Blood Line Set for Hemodialysis and others.
52GF Score
Get the complete analysis for ROCO:4115
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4115 has been successfully added to your 
